Larimar Therapeutics, Inc.(LRMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LRMR Larimar Therapeutics, Inc.

Trading 04-29 14:58:49 EDT

4.27

-0.13

-2.95%

High4.38	Low4.19	Vol1.19M
Open4.38	D1 Closing4.40	Amplitude4.32%
Mkt Cap444.08M	Tradable Cap314.53M	Total Shares104.00M
T/O5.05M	T/O Rate1.61%	Tradable Shares73.66M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LRMR","market":"US","secType":"STK","nameCN":"Larimar Therapeutics, Inc.","latestPrice":4.27,"timestamp":1777489127231,"preClose":4.4,"halted":0,"volume":1188704,"delay":0,"changeRate":-0.029545454545454722,"floatShares":73659546,"shares":104000000,"eps":-2.271113,"marketStatus":"Trading","change":-0.13,"latestTime":"04-29 14:58:49 EDT","open":4.38,"high":4.38,"low":4.19,"amount":5051023.9194624,"amplitude":0.043182,"askPrice":4.27,"askSize":616,"bidPrice":4.26,"bidSize":1017,"shortable":3,"etf":0,"ttmEps":-2.271113,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1777492800000},"marketStatusCode":2,"adr":0,"listingDate":1403150400000,"exchange":"NASDAQ","adjPreClose":4.4,"preHourTrading":{"tag":"盘前","latestPrice":4.37,"preClose":4.4,"latestTime":"09:29 EDT","volume":683,"amount":2946.635482,"timestamp":1777469399999,"change":-0.03,"changeRate":-0.006818,"amplitude":0.025841},"postHourTrading":{"tag":"盘后","latestPrice":4.41,"preClose":4.4,"latestTime":"19:31 EDT","volume":2973,"amount":13087.77,"timestamp":1777419095013,"change":0.01,"changeRate":0.002273,"amplitude":0.002273},"volumeRatio":1.152715,"impliedVol":1.6815,"impliedVolPercentile":0.4821},"requestUrl":"/m/hq/s/LRMR/tweets","defaultTab":"tweets","newsList":[{"id":"2629844585","title":"Larimar Therapeutics Inc  expected to post a loss of 54 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2629844585","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629844585?lang=en_us&edition=fundamental","pubTime":"2026-04-24 21:06","pubTimestamp":1777035970,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics Inc  expected to post a loss of54cents a share - Earnings Preview Larimar Therapeutics Inc LRMR.OQ LRMR.O is expected to  show no change in quarterly revenue when it reports  resu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nL8N4171KD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LRMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626110719","title":"Larimar Therapeutics announces annual stockholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2626110719","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626110719?lang=en_us&edition=fundamental","pubTime":"2026-04-11 04:13","pubTimestamp":1775851983,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics scheduled 2026 annual meeting of stockholders for May 19, 2026, to be held virtually.Shareholders will vote on election of three Class III directors for terms expiring at 2029 annual meeting.Meeting agenda includes advisory vote on executive compensation, plus advisory vote on preferred frequency of future say-on-pay votes.Stockholders will also vote on charter amendment to raise authorized common shares to 215,000,000 from 115,000,000, plus proposal to adjourn meeting if needed to secure votes for that share increase.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Larimar Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrie","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL9LRGjf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LRMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624130795","title":"Nomlabofusp’s Manageable Risk, Strong Efficacy Signals, and Significant FA Market Upside Underpin Buy Rating on LRMR","url":"https://stock-news.laohu8.com/highlight/detail?id=2624130795","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624130795?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:15","pubTimestamp":1775045728,"startTime":"0","endTime":"0","summary":"Analyst Francois Brisebois from LifeSci Capital maintained a Buy rating on Larimar Therapeutics and keeping the price target at $25.00. Francois Br...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/nomlabofusps-manageable-risk-strong-efficacy-signals-and-significant-fa-market-upside-underpin-buy-rating-on-lrmr-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/nomlabofusps-manageable-risk-strong-efficacy-signals-and-significant-fa-market-upside-underpin-buy-rating-on-lrmr-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LRMR","FA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621709185","title":"Larimar Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2621709185","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621709185?lang=en_us&edition=fundamental","pubTime":"2026-03-23 21:31","pubTimestamp":1774272698,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryLarimar Therapeutics Inc LRMR.OQ reported a quarterly adjusted loss of 73 cents per share for the quarter e","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nL8N40B1D3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LRMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620366327","title":"Larimar Therapeutics Inc  expected to post a loss of 52 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2620366327","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620366327?lang=en_us&edition=fundamental","pubTime":"2026-03-20 20:41","pubTimestamp":1774010466,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics Inc  expected to post a loss of52cents a share - Earnings Preview Larimar Therapeutics Inc LRMR.OQ LRMR.O is expected to  show no change in quarterly revenue when it reports  resu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nL8N40815S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LRMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620778034","title":"Citi Reaffirms Their Buy Rating on Larimar Therapeutics (LRMR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620778034","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620778034?lang=en_us&edition=fundamental","pubTime":"2026-03-20 18:57","pubTimestamp":1774004237,"startTime":"0","endTime":"0","summary":"Citi analyst Samantha Semenkow reiterated a Buy rating on Larimar Therapeutics today and set a price target of $14.00. Semenkow covers the Healthca...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/citi-reaffirms-their-buy-rating-on-larimar-therapeutics-lrmr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/citi-reaffirms-their-buy-rating-on-larimar-therapeutics-lrmr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LRMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620244623","title":"Larimar Therapeutics Q4 net loss rises more than doubled to USD 62.5 million as R&D expenses jump more than doubled to USD 59.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620244623","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620244623?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:05","pubTimestamp":1773918311,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics Q4 net loss rises more than doubled to USD 62.5 million as R&D expenses jump more than doubled to USD 59.4 million. Larimar published a fourth-quarter and full-year 2025 financial results press release.Q4 net loss widened 117% to USD 62.5 million, while R&D expense rose 122% to USD 59.37 million, driven mainly by higher nomlabofusp manufacturing costs tied to process performance qualification and commercialization scale-up.For FY 2025, net loss increased 106% to USD 165.67 million and R&D expense rose 110% to USD 154.22 million, primarily reflecting higher nomlabofusp manufacturing costs and increased clinical, quality, and regulatory activity.Cash, cash equivalents and marketable securities totaled USD 136.9 million at year-end, and pro forma cash, cash equivalents and marketable securities were USD 244.5 million following USD 107.6 million in net proceeds from a February 2026 public offering.Nomlabofusp updates included FDA Breakthrough Therapy Designation, topli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL4vJpDm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014005.SGD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","LRMR","SG9999014039.USD","LU2095319765.USD","LU2210149790.SGD","BK4585","IE00BGHQF748.EUR","BK4588","NDAQ","LU0314104364.USD","SG9999014021.USD","BK4139","LU2210150020.SGD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620424101","title":"BRIEF-Larimar Therapeutics Q4 Net Income USD -62.498 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620424101","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620424101?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:00","pubTimestamp":1773918048,"startTime":"0","endTime":"0","summary":"BRIEF-Larimar Therapeutics Q4 Net Income USD -62.498 Million\n\n\nMar 19 (Reuters) - Larimar Therapeutics Q4 income from operations USD -64.018 million.\n\nQ4 operating expenses USD 64.018 million\nQ4 EPS USD -0.73","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nPLX9116CD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LRMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620410012","title":"Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2620410012","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620410012?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:00","pubTimestamp":1773918004,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nTUACGLSBH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LRMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620958244","title":"Larimar Therapeutics Inc - Bla Submission Planned for June 2026; U.S. Launch Targeted First-Half 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2620958244","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620958244?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:00","pubTimestamp":1773918003,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nPLX9116CD:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LRMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620244864","title":"Larimar Therapeutics Q4 EPS USD -0.73","url":"https://stock-news.laohu8.com/highlight/detail?id=2620244864","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620244864?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:00","pubTimestamp":1773918003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nPLX9116CD:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LRMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620244810","title":"Larimar Therapeutics Q4 Operating Expenses USD 64.018 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620244810","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620244810?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:00","pubTimestamp":1773918003,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nPLX9116CD:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LRMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620244674","title":"Larimar Therapeutics Inc - Topline Open Label Study Data Expected in Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620244674","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620244674?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:00","pubTimestamp":1773918003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nPLX9116CD:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LRMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616393314","title":"James E. Flynn, Director, Acquires Larimar Therapeutics Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2616393314","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616393314?lang=en_us&edition=fundamental","pubTime":"2026-03-03 08:46","pubTimestamp":1772498817,"startTime":"0","endTime":"0","summary":"James E. Flynn, Director and 10% Owner, reported an acquisition of common shares of Larimar Therapeutics, Inc. Reporting owners also included Deerfield Management Company, L.P., Deerfield Mgmt III, L.P., and Deerfield Partners, L.P., along with other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Larimar Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL2pnSdm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LRMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616369092","title":"Larimar Therapeutics Director Jeffrey W. Sherman Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2616369092","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616369092?lang=en_us&edition=fundamental","pubTime":"2026-03-03 05:34","pubTimestamp":1772487272,"startTime":"0","endTime":"0","summary":"Jeffrey W. Sherman, a director of Larimar Therapeutics, Inc., reported acquiring 5,000 shares of the company’s common stock. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Larimar Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL2T4ysf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Larimar Therapeutics Director Jeffrey W. Sherman Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LRMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614981087","title":"Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Larimar Therapeutics (LRMR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614981087","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614981087?lang=en_us&edition=fundamental","pubTime":"2026-02-28 23:30","pubTimestamp":1772292608,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Palvella Therapeutics (PVLA – Research Report) and L...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-palvella-therapeutics-pvla-and-larimar-therapeutics-lrmr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-palvella-therapeutics-pvla-and-larimar-therapeutics-lrmr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","HCSG","LU0128526141.USD","BK4137","LABU","PVLA","XBI","LU0029874061.USD","XLV","BK4585","LRMR","BK4581","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614426620","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2614426620","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614426620?lang=en_us&edition=fundamental","pubTime":"2026-02-26 21:22","pubTimestamp":1772112120,"startTime":"0","endTime":"0","summary":"Procept BioRobotics  shares were down 24% in recent Thursday premarket activity, a day after the company posted a wider Q4 net loss and BofA Securities downgraded the company's stock to underperform from neutral.The Trade Desk  stock was down 17%, a day after the company issued lower-than-expected Q1 revenue guidance.Vir Biotechnology  shares were 16% lower after the company said overnight it priced an underwritten offering of about 17.6 million of its common shares for expected gross proceeds of $150 million.Larimar Therapeutics  stock was down 11%, a day after the company said it priced an upsized public offering of 20 million common shares at $5 each to raise $100 million.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4082","TTD","TTDU","BK4613","LU2324357040.USD","LU1720051108.HKD","LU0348723411.USD","PRCT","BK4535","BK4548","BK4139","BK4009","VIR","LU1548497426.USD","BK4528","BK4023","LU2357305700.SGD","BK4585","BK4568","LU1720051017.SGD","BK4588","LRMR"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2614616400","title":"Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2614616400","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614616400?lang=en_us&edition=fundamental","pubTime":"2026-02-26 09:59","pubTimestamp":1772071187,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUA62RBQK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LRMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614061647","title":"Larimar Therapeutics Inc - Prices Upsized Public Offering at $5.00 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2614061647","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614061647?lang=en_us&edition=fundamental","pubTime":"2026-02-26 09:59","pubTimestamp":1772071187,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUA62RBQK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LRMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614059270","title":"BUZZ-Larimar Therapeutics slips after $75 mln stock offering commenced","url":"https://stock-news.laohu8.com/highlight/detail?id=2614059270","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614059270?lang=en_us&edition=fundamental","pubTime":"2026-02-26 05:25","pubTimestamp":1772054735,"startTime":"0","endTime":"0","summary":"** Larimar Therapeutics LRMR.O shares down 5.4% at $5.63. in extended trading as it seeks equity raise after seeing its stock more than double in the past two sessions. ** LRMR shares finished up 61.2% at $5.95 on Weds following 31% surge on Tues after the U.S. FDA granted 'breakthrough' tag for co's neurological disorder therapy, nomlabofusp. ** Bala Cynwyd, Pennsylvania-based firm after the bell commences $75 mln offering comprising shares and pre-funded warrants. ** Co intends to use net offering proceeds to support development of nomlabofusp and for working capital and general corporate purposes, including R&D and commercialization expenses** JP Morgan and Guggenheim joint bookrunners** Co has ~83 mln shares outstanding for roughly $500 mln market cap, per LSEG. ** All 11 analysts are bullish including 7 \"strong buy\" ratings; median PT $16","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nL6N3ZL1AM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0006306889.USD","LU0345770993.USD","LU0943347566.SGD","LU0320765646.SGD","LU2023250843.SGD","LU0787776722.HKD","LU1670628061.USD","LU1894683264.USD","LU2242649171.HKD","IE00BJTD4N35.SGD","LRMR","IE0034235295.USD","LU0070302665.USD","LU1267930490.SGD","LU0238689110.USD","BK4534","LU2552382132.HKD","BK4139","BK4550","LU1551013342.USD","LU0170899867.USD","LU1551013425.SGD","IE00BBT3K403.USD","LU2054465674.USD","LU0265550359.USD","LU2552382058.USD","IE00B1BXHZ80.USD","LU1116320737.USD","BK4207","BK4516","LU1720051108.HKD","LU0820562030.AUD","LU0976567544.SGD","LU2746668974.SGD","JPO","LU2237443622.USD","BK4581","LU1496350502.SGD","LU2106854487.HKD","LU2746668461.USD","LU1162221912.USD","LU0323591593.USD","LU0689472784.USD","BK4533","LU0820561909.HKD","LU2417539215.USD","LU0215105999.USD","LU2756315318.SGD","LU2264538146.SGD","JPMO","LU1914381329.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.larimartx.com","stockEarnings":[{"period":"1week","weight":-0.0372},{"period":"1month","weight":-0.0476},{"period":"3month","weight":0.1957},{"period":"6month","weight":0.0891},{"period":"1year","weight":0.8723},{"period":"ytd","weight":0.1549}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.1224},{"period":"3month","weight":0.0234},{"period":"6month","weight":0.0469},{"period":"1year","weight":0.292},{"period":"ytd","weight":0.0437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.583333,"avgChangeRate":0.088036},{"month":2,"riseRate":0.583333,"avgChangeRate":0.090114},{"month":3,"riseRate":0.25,"avgChangeRate":-0.145723},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.027753},{"month":5,"riseRate":0.454545,"avgChangeRate":-0.091938},{"month":6,"riseRate":0.545455,"avgChangeRate":0.006336},{"month":7,"riseRate":0.5,"avgChangeRate":-0.021968},{"month":8,"riseRate":0.5,"avgChangeRate":0.081374},{"month":9,"riseRate":0.416667,"avgChangeRate":0.000938},{"month":10,"riseRate":0.666667,"avgChangeRate":-0.029427},{"month":11,"riseRate":0.583333,"avgChangeRate":0.038429},{"month":12,"riseRate":0.583333,"avgChangeRate":0.050649}],"exchange":"NASDAQ","name":"Larimar Therapeutics, Inc.","nameEN":"Larimar Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Larimar Therapeutics, Inc.(LRMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Larimar Therapeutics, Inc.(LRMR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Larimar Therapeutics, Inc.,LRMR,Larimar Therapeutics, Inc.股票,Larimar Therapeutics, Inc.股票老虎,Larimar Therapeutics, Inc.股票老虎国际,Larimar Therapeutics, Inc.行情,Larimar Therapeutics, Inc.股票行情,Larimar Therapeutics, Inc.股价,Larimar Therapeutics, Inc.股市,Larimar Therapeutics, Inc.股票价格,Larimar Therapeutics, Inc.股票交易,Larimar Therapeutics, Inc.股票购买,Larimar Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Larimar Therapeutics, Inc.(LRMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Larimar Therapeutics, Inc.(LRMR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction